KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Weighted Average and Diluted) (2021 - 2026)

TherapeuticsMD filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.01 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 116.67% to $0.01 in Q1 2026 year-over-year; TTM through Dec 2025 was -$0.07, a 63.16% increase, with the full-year FY2025 number at -$0.06, up 68.42% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.01 in Q1 2026 for TherapeuticsMD, up from -$0.06 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.45 in Q4 2022 to a low of -$2.08 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.07 (2024), compared with a mean of -$0.07.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 209.44% in 2022 and later plummeted 400.0% in 2025.
  • TherapeuticsMD's EPS (Weighted Average and Diluted) stood at $5.45 in 2022, then plummeted by 102.57% to -$0.14 in 2023, then skyrocketed by 114.29% to $0.02 in 2024, then plummeted by 400.0% to -$0.06 in 2025, then soared by 116.67% to $0.01 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.01 (Q1 2026), -$0.06 (Q4 2025), and $0.01 (Q3 2025) per Business Quant data.